# Alto Neuroscience, Inc.: financial statements, quarterly

ANRO · NYSE · CIK 1999480 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/anro.md) · [Financials](/companies/anro/financials.md) · [Filings](/companies/anro/filings.md) · [Insiders](/companies/anro/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/anro/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [8.0](/filings/0001999480-24-000042.md) | [9.6 d](/filings/0001999480-25-000025.md) | [10.0](/filings/0001999480-25-000037.md) | [13.2](/filings/0001999480-25-000076.md) | [13.1](/filings/0001999480-25-000090.md) | [10.8 d](/filings/0001999480-26-000002.md) | [10.0](/filings/0001999480-26-000012.md) | [13.1](/filings/0001999480-26-000023.md) | [10.5](/filings/0001999480-25-000090.md) | [12.0 d](/filings/0001999480-26-000002.md) | [20.3](/filings/0001999480-26-000012.md) | [22.1](/filings/0001999480-26-000023.md) |
| Operating income | $m | [(9.7)](/filings/0001999480-24-000042.md) | [(11.8) d](/filings/0001999480-25-000025.md) | [(14.4)](/filings/0001999480-25-000037.md) | [(18.3)](/filings/0001999480-25-000076.md) | [(18.9)](/filings/0001999480-25-000090.md) | [(17.0) d](/filings/0001999480-26-000002.md) | [(15.7)](/filings/0001999480-26-000012.md) | [(18.7)](/filings/0001999480-26-000023.md) | [(15.0)](/filings/0001999480-25-000090.md) | [(17.1) d](/filings/0001999480-26-000002.md) | [(27.1)](/filings/0001999480-26-000012.md) | [(29.1)](/filings/0001999480-26-000023.md) |
| Interest expense | $m | [0.4](/filings/0001999480-24-000042.md) | [0.4 d](/filings/0001999480-25-000025.md) | [0.3](/filings/0001999480-25-000037.md) | [0.3](/filings/0001999480-25-000076.md) | [0.3](/filings/0001999480-25-000090.md) | [0.3 d](/filings/0001999480-26-000002.md) | [0.6](/filings/0001999480-26-000012.md) | [0.6](/filings/0001999480-26-000023.md) | [0.7](/filings/0001999480-25-000090.md) | [0.6 d](/filings/0001999480-26-000002.md) | [0.5](/filings/0001999480-26-000012.md) | [0.5](/filings/0001999480-26-000023.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001999480-24-000022.md) | [0.0 d](/filings/0001999480-24-000035.md) | [0.0 d](/filings/0001999480-24-000042.md) | [0.0 d](/filings/0001999480-26-000002.md) | [0.0](/filings/0001999480-25-000037.md) | [0.0 d](/filings/0001999480-25-000076.md) | [0.0 d](/filings/0001999480-25-000090.md) | [0.0 d](/filings/0001999480-26-000002.md) | not reported | not reported |
| Net income | $m | [(9.1)](/filings/0001999480-24-000042.md) | [(11.2) d](/filings/0001999480-25-000025.md) | [(13.4)](/filings/0001999480-25-000090.md) | [(16.0)](/filings/0001999480-25-000090.md) | [(16.8)](/filings/0001999480-25-000090.md) | [(15.2) d](/filings/0001999480-26-000002.md) | [(15.2)](/filings/0001999480-26-000023.md) | [(17.7)](/filings/0001999480-26-000023.md) | [(14.2)](/filings/0001999480-25-000090.md) | [(16.2) d](/filings/0001999480-26-000002.md) | [(26.2)](/filings/0001999480-26-000023.md) | [(27.6)](/filings/0001999480-26-000023.md) |
| Diluted EPS | $ per share | [(2.44)](/filings/0001999480-24-000042.md) | not reported | [(0.76)](/filings/0001999480-25-000037.md) | [(0.60)](/filings/0001999480-25-000076.md) | [(0.62)](/filings/0001999480-25-000090.md) | not reported | [(0.56)](/filings/0001999480-26-000012.md) | [(0.65)](/filings/0001999480-26-000023.md) | [(0.52)](/filings/0001999480-25-000090.md) | not reported | [(0.80)](/filings/0001999480-26-000012.md) | [(0.65)](/filings/0001999480-26-000023.md) |
| Basic EPS | $ per share | [(2.44)](/filings/0001999480-24-000042.md) | not reported | [(0.76)](/filings/0001999480-25-000037.md) | [(0.60)](/filings/0001999480-25-000076.md) | [(0.62)](/filings/0001999480-25-000090.md) | not reported | [(0.56)](/filings/0001999480-26-000012.md) | [(0.65)](/filings/0001999480-26-000023.md) | [(0.52)](/filings/0001999480-25-000090.md) | not reported | [(0.80)](/filings/0001999480-26-000012.md) | [(0.65)](/filings/0001999480-26-000023.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [82.5](/filings/0001999480-25-000025.md) | [206](/filings/0001999480-24-000022.md) | [193](/filings/0001999480-24-000035.md) | [182](/filings/0001999480-24-000042.md) | [168](/filings/0001999480-26-000002.md) | [161](/filings/0001999480-25-000037.md) | [148](/filings/0001999480-25-000076.md) | [138](/filings/0001999480-25-000090.md) | [176](/filings/0001999480-26-000023.md) | [264](/filings/0001999480-26-000012.md) | [244](/filings/0001999480-26-000023.md) |
| Current assets | $m | not reported | [85.4](/filings/0001999480-25-000025.md) | [208](/filings/0001999480-24-000022.md) | [195](/filings/0001999480-24-000035.md) | [184](/filings/0001999480-24-000042.md) | [169](/filings/0001999480-26-000002.md) | [164](/filings/0001999480-25-000037.md) | [150](/filings/0001999480-25-000076.md) | [139](/filings/0001999480-25-000090.md) | [178](/filings/0001999480-26-000023.md) | [269](/filings/0001999480-26-000012.md) | [247](/filings/0001999480-26-000023.md) |
| Total assets | $m | not reported | [86.6](/filings/0001999480-25-000025.md) | [210](/filings/0001999480-24-000022.md) | [197](/filings/0001999480-24-000035.md) | [192](/filings/0001999480-24-000042.md) | [178](/filings/0001999480-26-000002.md) | [172](/filings/0001999480-25-000037.md) | [158](/filings/0001999480-25-000076.md) | [147](/filings/0001999480-25-000090.md) | [185](/filings/0001999480-26-000023.md) | [276](/filings/0001999480-26-000012.md) | [254](/filings/0001999480-26-000023.md) |
| Current liabilities | $m | not reported | [5.6](/filings/0001999480-25-000025.md) | [8.0](/filings/0001999480-24-000022.md) | [9.8](/filings/0001999480-24-000035.md) | [14.0](/filings/0001999480-24-000042.md) | [10.0](/filings/0001999480-26-000002.md) | [7.3](/filings/0001999480-25-000037.md) | [8.1](/filings/0001999480-25-000076.md) | [9.0](/filings/0001999480-25-000090.md) | [11.3](/filings/0001999480-26-000023.md) | [13.1](/filings/0001999480-26-000012.md) | [16.7](/filings/0001999480-26-000023.md) |
| Total liabilities | $m | not reported | [16.8](/filings/0001999480-25-000025.md) | [16.8](/filings/0001999480-24-000022.md) | [17.6](/filings/0001999480-24-000035.md) | [26.6](/filings/0001999480-24-000042.md) | [26.1](/filings/0001999480-26-000002.md) | [32.8](/filings/0001999480-25-000037.md) | [34.5](/filings/0001999480-25-000076.md) | [35.4](/filings/0001999480-25-000090.md) | [33.5](/filings/0001999480-26-000023.md) | [32.9](/filings/0001999480-26-000012.md) | [34.8](/filings/0001999480-26-000023.md) |
| Long-term debt | $m | not reported | [9.9](/filings/0001999480-25-000025.md) | [8.8](/filings/0001999480-24-000022.md) | [7.7](/filings/0001999480-24-000035.md) | [6.6](/filings/0001999480-24-000042.md) | [10.3](/filings/0001999480-26-000002.md) | [19.9](/filings/0001999480-25-000037.md) | [20.1](/filings/0001999480-25-000076.md) | [20.3](/filings/0001999480-25-000090.md) | [16.2](/filings/0001999480-26-000023.md) | [13.9](/filings/0001999480-26-000012.md) | [12.4](/filings/0001999480-26-000023.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001999480-24-000042.md) | [1.1](/filings/0001999480-24-000022.md) | [2.3](/filings/0001999480-24-000035.md) | [3.5](/filings/0001999480-24-000042.md) | [0.0](/filings/0001999480-26-000002.md) | not reported | not reported | not reported | [0.6](/filings/0001999480-26-000023.md) | [2.1](/filings/0001999480-26-000012.md) | [3.8](/filings/0001999480-26-000023.md) |
| Shareholders' equity | $m | [(61.1)](/filings/0001999480-24-000042.md) | [(71.7)](/filings/0001999480-26-000002.md) | [193](/filings/0001999480-25-000090.md) | [180](/filings/0001999480-25-000090.md) | [165](/filings/0001999480-25-000090.md) | [151](/filings/0001999480-26-000023.md) | [139](/filings/0001999480-26-000023.md) | [123](/filings/0001999480-26-000023.md) | [112](/filings/0001999480-25-000090.md) | [151](/filings/0001999480-26-000023.md) | [243](/filings/0001999480-26-000023.md) | [219](/filings/0001999480-26-000023.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.8) d](/filings/0001999480-24-000042.md) | [(11.5) d](/filings/0001999480-25-000025.md) | [(11.0)](/filings/0001999480-25-000037.md) | [(11.7) d](/filings/0001999480-25-000076.md) | [(11.7) d](/filings/0001999480-25-000090.md) | [(13.0) d](/filings/0001999480-26-000002.md) | [(16.6)](/filings/0001999480-26-000012.md) | [(13.8) d](/filings/0001999480-26-000023.md) | [(9.9) d](/filings/0001999480-25-000090.md) | [(11.5) d](/filings/0001999480-26-000002.md) | [(27.1)](/filings/0001999480-26-000012.md) | [(19.8) d](/filings/0001999480-26-000023.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001999480-24-000042.md) | [0.4 d](/filings/0001999480-25-000025.md) | [0.2](/filings/0001999480-25-000037.md) | [0.3 d](/filings/0001999480-25-000076.md) | [1.0 d](/filings/0001999480-25-000090.md) | [0.5 d](/filings/0001999480-26-000002.md) | [0.0](/filings/0001999480-26-000012.md) | [0.0 d](/filings/0001999480-26-000023.md) | [0.0 d](/filings/0001999480-25-000090.md) | [0.0 d](/filings/0001999480-26-000002.md) | [0.6](/filings/0001999480-26-000012.md) | [0.0 d](/filings/0001999480-26-000023.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.7](/filings/0001999480-24-000022.md) | [3.7](/filings/0001999480-24-000035.md) | [3.7](/filings/0001999480-24-000042.md) | [17.6](/filings/0001999480-25-000037.md) | [26.9](/filings/0001999480-25-000076.md) | [27.0](/filings/0001999480-25-000090.md) | [27.0](/filings/0001999480-26-000012.md) | [27.1](/filings/0001999480-26-000023.md) | [27.1](/filings/0001999480-25-000090.md) | [32.9](/filings/0001999480-26-000012.md) | [42.8](/filings/0001999480-26-000023.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 39,242,104 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001999480-26-000023.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.